HER2-positive breast cancer is a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer cells. This type of breast cancer is more aggresive than other types of breast cancer.

The drug neratinib (Nerlynx, Puma Biotechnology) was approved by the US Food and Drug Administration as an adjuvant of the treatment of HER2-positive breast cancer.

According to a pivotal phase 3 randomized clinical trial performed on 2840 patients with early stage HER2-positive breast, the 1 year  administration of neratinib led to a disease-free survival rate of 94.2%, comparable with 91,9% at patients treated with placebo. Patients received the study drug and placebo after the treatment with trastuzumab.

The pharmacological action of neratinib is determined by the inhibition of tyrosine kinase and it works by blocking several enzyme that promote the grown of the cancer cells.

More information can be found here.